NCT01079988: Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence |
|
|
| Completed | 4 | 41 | Canada | Cyclosporins, Retinoids, Systemic corticosteroids, Methotrexate, Systemic corticosteroids/methotrexate | Merck KGaA, Darmstadt, Germany | Psoriasis | 12/04 | 04/05 | | |
